Clinical Report: Comparative Analysis of Surgical Intervention in Pancreatic Cancer

Overview

This multicenter retrospective study compares outcomes of upfront surgery (US) versus neoadjuvant therapy (NAT) in pancreatic cancer patients with suspected venous involvement. The findings indicate significant differences in patient characteristics and outcomes between the two treatment approaches.

Background

Pancreatic cancer is often diagnosed at an advanced stage, with limited options for curative treatment. The management of venous involvement in pancreatic cancer remains controversial, with varying guidelines recommending either neoadjuvant therapy or upfront surgery. Understanding the outcomes associated with these approaches is critical for optimizing treatment strategies.

Data Highlights

Key Findings

• The US cohort was older than the NAT cohort (66.5 years).

• Short-term morbidity and mortality were assessed at 30 and 90 days post-surgery.

• Long-term outcomes included overall and disease-free survival rates.

• Patients were categorized based on treatment received: US or NAT.

• Statistical analyses were performed to evaluate differences in outcomes between groups.

Clinical Implications

The study highlights the need for careful consideration of treatment approaches in pancreatic cancer patients with venous involvement. Clinicians should weigh the potential benefits and risks of neoadjuvant therapy versus upfront surgery based on individual patient characteristics.

Conclusion

Among patients with pancreatic cancer and suspected venous involvement, treatment outcomes differed between those who underwent upfront surgery and those who received neoadjuvant therapy. Their findings support individualized treatment decisions, taking patient characteristics and the potential benefits and risks of each approach into account. The available information does not specify the authors’ detailed comparative conclusions or identify one approach as superior.

Related Resources & Content

1. Comprehensive Review and Meta-Analysis of Modern Pancreatic Surgery Involving Arterial Resection, Springer, 2020 -- Title

2. Outcomes After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma, ASCO Post, 2023 -- Title

3. VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer, ASCO Post, 2026 -- Title

4. NCCN Guidelines Version 2.2025, NCCN -- Title

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer, PMC -- Title

6. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?, PubMed -- Title

7. the asco post — VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer

8. NCCN Guidelines Version 2.2025

9. Pan-Asian adapted ESMO Clinical Practice Guidelines

10. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy

11. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? - PubMed

12. Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials - ScienceDirect

13. Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA). - ASCO

14. Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: A Systematic Review and Meta-Analysis - PMC